Protalix BioTherapeutics (PLX) Competitors $2.96 +0.11 (+3.86%) Closing price 04/29/2025 04:00 PM EasternExtended Trading$2.95 -0.01 (-0.34%) As of 04/29/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock PLX vs. ELVN, OCS, GYRE, VIR, AVDL, RCKT, PHVS, XNCR, AVXL, and ABCLShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Enliven Therapeutics (ELVN), Oculis (OCS), Gyre Therapeutics (GYRE), Vir Biotechnology (VIR), Avadel Pharmaceuticals (AVDL), Rocket Pharmaceuticals (RCKT), Pharvaris (PHVS), Xencor (XNCR), Anavex Life Sciences (AVXL), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Enliven Therapeutics Oculis Gyre Therapeutics Vir Biotechnology Avadel Pharmaceuticals Rocket Pharmaceuticals Pharvaris Xencor Anavex Life Sciences AbCellera Biologics Enliven Therapeutics (NASDAQ:ELVN) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability, community ranking and earnings. Do analysts prefer ELVN or PLX? Enliven Therapeutics currently has a consensus price target of $40.33, suggesting a potential upside of 116.26%. Protalix BioTherapeutics has a consensus price target of $15.00, suggesting a potential upside of 406.76%. Given Protalix BioTherapeutics' higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Enliven Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ELVN or PLX? Enliven Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Does the media prefer ELVN or PLX? In the previous week, Enliven Therapeutics had 6 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 7 mentions for Enliven Therapeutics and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.76 beat Enliven Therapeutics' score of 1.08 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is ELVN or PLX more profitable? Enliven Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Enliven Therapeutics' return on equity of -29.46% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -29.46% -27.33% Protalix BioTherapeutics -21.03%-30.89%-11.74% Do insiders and institutionals hold more shares of ELVN or PLX? 95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 29.2% of Enliven Therapeutics shares are owned by insiders. Comparatively, 6.3% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in ELVN or PLX? Protalix BioTherapeutics received 1 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 80.00% of users gave Protalix BioTherapeutics an outperform vote. CompanyUnderperformOutperformEnliven TherapeuticsOutperform Votes11100.00% Underperform VotesNo VotesProtalix BioTherapeuticsOutperform Votes1280.00% Underperform Votes320.00% Which has stronger earnings and valuation, ELVN or PLX? Protalix BioTherapeutics has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$71.58M-$1.89-9.87Protalix BioTherapeutics$53.40M4.33$8.31M$0.0398.67 SummaryEnliven Therapeutics beats Protalix BioTherapeutics on 11 of the 18 factors compared between the two stocks. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$230.98M$2.96B$5.51B$18.93BDividend YieldN/A1.89%5.11%4.04%P/E Ratio-22.7729.8222.4032.80Price / Sales4.33492.56399.7428.88Price / Cash17.80168.6838.1817.53Price / Book6.303.196.744.48Net Income$8.31M-$72.17M$3.22B$1.02B7 Day PerformanceN/A1.48%2.40%2.60%1 Month Performance14.73%-1.82%-0.83%-2.55%1 Year Performance159.65%-22.14%17.79%5.89% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeutics2.6969 of 5 stars$2.96+3.9%$15.00+406.8%+148.7%$230.98M$53.40M-22.77200News CoveragePositive NewsELVNEnliven Therapeutics2.2554 of 5 stars$16.22-1.9%$40.33+148.7%+4.8%$794.85MN/A-8.5450News CoveragePositive NewsGap DownOCSOculis2.8829 of 5 stars$18.12-0.8%$30.25+66.9%+38.0%$791.16M$980,000.00-9.392Short Interest ↓GYREGyre Therapeutics0.0861 of 5 stars$8.40-5.4%N/A-41.8%$786.34M$105.76M168.0040VIRVir Biotechnology2.6045 of 5 stars$5.61+2.0%$33.57+498.4%-28.6%$769.37M$63.71M-1.43580Upcoming EarningsAVDLAvadel Pharmaceuticals2.3098 of 5 stars$7.96-0.9%$19.88+149.7%-52.1%$769.17M$169.12M-10.0870Upcoming EarningsPositive NewsRCKTRocket Pharmaceuticals4.6407 of 5 stars$7.17+13.3%$43.00+499.7%-66.7%$764.54MN/A-2.61240Upcoming EarningsHigh Trading VolumePHVSPharvaris2.2668 of 5 stars$14.50+3.6%$40.50+179.3%-26.4%$758.21MN/A-5.1830Analyst ForecastPositive NewsGap UpXNCRXencor3.3583 of 5 stars$10.60+9.3%$33.86+219.4%-49.8%$746.90M$110.49M-3.31280AVXLAnavex Life Sciences3.8377 of 5 stars$8.76-2.1%$44.00+402.3%+163.8%$745.16MN/A-15.9340Positive NewsABCLAbCellera Biologics2.6454 of 5 stars$2.45+1.2%$7.50+206.1%-33.6%$730.07M$28.83M-4.02500Gap Down Related Companies and Tools Related Companies Enliven Therapeutics Alternatives Oculis Alternatives Gyre Therapeutics Alternatives Vir Biotechnology Alternatives Avadel Pharmaceuticals Alternatives Rocket Pharmaceuticals Alternatives Pharvaris Alternatives Xencor Alternatives Anavex Life Sciences Alternatives AbCellera Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PLX) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Silent Heist Draining Your Retirement SavingsU.S. Debt Crisis - A Silent Heist of Your Retirement Savings Americans are losing wealth daily and don't ev...American Hartford Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLX Stock Free PLX Stock Alerts